Arkema SA (OTCMKTS:ARKAY – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $60.56, but opened at $67.65. Arkema shares last traded at $68.09, with a volume of 458 shares traded.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on ARKAY shares. Deutsche Bank Aktiengesellschaft lowered shares of Arkema from a “buy” rating to a “hold” rating in a research report on Monday, November 24th. Barclays lowered Arkema from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 11th. Finally, Zacks Research lowered Arkema from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce”.
View Our Latest Analysis on ARKAY
Arkema Price Performance
Arkema (OTCMKTS:ARKAY – Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The basic materials company reported $1.19 EPS for the quarter, beating the consensus estimate of $0.98 by $0.21. Arkema had a return on equity of 5.15% and a net margin of 1.55%.The business had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. As a group, sell-side analysts expect that Arkema SA will post 8.36 earnings per share for the current fiscal year.
Arkema Company Profile
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total’s chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema’s operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
Recommended Stories
- Five stocks we like better than Arkema
- Why This NYSE Biotech Matters in 2026
- [No Brainer Gold Play]: “Show me a better investment.”
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- This Company Surges Ahead as AI Marketing Fuels Record Revenue
Receive News & Ratings for Arkema Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arkema and related companies with MarketBeat.com's FREE daily email newsletter.
